Corrigendum to “Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6” [J Crohns Colitis 8S1 (2014) P497 S274-5]

The authors regret that an inaccuracy in the published abstract has been brought to their attention and is described below. In the table, the 95% confidence interval for the proportion of week 6 nonresponders who had a CDAI-100 response at week 10 among the placebo group should be changed from (3.0, 17.3) to (1.1, 13.4). For convenience, we present the complete corrected data in the revised version of the table below. Data are % of patients. Prespecified analysis. Post hoc analysis. Data are % of patients. Prespecified analysis. Post hoc analysis. Please note that the revision described above does not alter the interpretation of the effect of vedolizumab on the end points of the analysis.